<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661126</url>
  </required_header>
  <id_info>
    <org_study_id>3682B-030</org_study_id>
    <secondary_id>MK-3682B-030</secondary_id>
    <secondary_id>CA16919</secondary_id>
    <nct_id>NCT02661126</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)</brief_title>
  <official_title>A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3682B (MK-3682/MK-5172/MK-8408 Fixed Dose Combination) When Administered to Subjects With Moderate and Severe Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the plasma pharmacokinetics (PK) of single doses of
      MK-3682B, a fixed dose combination (FDC) tablet containing uprifosbuvir (MK-3682) +
      grazoprevir (MK-5172) + ruzasvir (MK-8408) in participants with moderate (Part 1) and severe
      (Part 2) renal insufficiency (RI) to plasma PK in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2016</start_date>
  <completion_date type="Actual">August 26, 2016</completion_date>
  <primary_completion_date type="Actual">August 26, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) From Dosing to Time of Last Measurable Concentration (AUC0-last) of Uprifosbuvir (MK-3682)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>AUC0-last is a measure of total exposure to uprifosbuvir in plasma from the start of dosing to the time of the last quantifiable (&lt; lower limit of quantification [LLOQ]) sample following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC From Dosing to Infinity (AUC0-∞) of Uprifosbuvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>AUC0-∞ is a measure of total exposure to uprifosbuvir in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC From Dosing to 24 Hours Post-dose (AUC0-24) of Uprifosbuvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose</time_frame>
    <description>AUC0-24 is a measure of total exposure to uprifosbuvir in plasma from dosing to 24 hours following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Uprifosbuvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Cmax is the maximum amount of uprifosbuvir in plasma following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration 24 Hours Post-dose (C24) of Uprifosbuvir</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>C24 is the plasma concentration of uprifosbuvir 24 hours following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of Uprifosbuvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Tmax is the time required to reach the maximum post-dose plasma concentration of uprifosbuvir following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) of Uprifosbuvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>CL/F is the apparent total body clearance of uprifosbuvir following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Uprifosbuvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Vz/F is the apparent volume of distribution of uprifosbuvir following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-life in Plasma (t½) of Uprifosbuvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>t1/2 is the amount of time required to clear 50% of uprifosbuvir from plasma following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last of Uprifosbuvir Metabolite M5</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>AUC0-last is a measure of total exposure to uprifosbuvir metabolite M5 in plasma from the start of dosing to the time of the last quantifiable (&lt;LLOQ) sample following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ of Uprifosbuvir Metabolite M5</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>AUC0-∞ is a measure of total exposure to uprifosbuvir metabolite M5 in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 of Uprifosbuvir Metabolite M5</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose</time_frame>
    <description>AUC0-24 is a measure of total exposure to uprifosbuvir metabolite M5 in plasma from dosing to 24 hours following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Uprifosbuvir Metabolite M5</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Cmax is the maximum amount of uprifosbuvir metabolite M5 in plasma following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C24 of Uprifosbuvir Metabolite M5</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>C24 is the plasma concentration of uprifosbuvir metabolite M5 24 hours following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Uprifosbuvir Metabolite M5</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Tmax is the time required to reach the maximum post-dose plasma concentration of uprifosbuvir metabolite M5 following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lag Time (Tlag) of Uprifosbuvir Metabolite M5</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Tlag is the time from dosing to first appearance in plasma of uprifosbuvir metabolite M5 following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t½ of Uprifosbuvir Metabolite M5</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>t1/2 is the amount of time required to clear 50% of uprifosbuvir metabolite M5 from plasma following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last of Uprifosbuvir Metabolite M6</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>AUC0-last is a measure of total exposure to uprifosbuvir metabolite M6 in plasma from the start of dosing to the time of the last quantifiable (&lt;LLOQ) sample following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ of Uprifosbuvir Metabolite M6</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>AUC0-∞ is a measure of total exposure to uprifosbuvir metabolite M6 in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 of Uprifosbuvir Metabolite M6</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose</time_frame>
    <description>AUC0-24 is a measure of total exposure to uprifosbuvir metabolite M6 in plasma from dosing to 24 hours following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Uprifosbuvir Metabolite M6</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Cmax is the maximum amount of uprifosbuvir metabolite M6 in plasma following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C24 of Uprifosbuvir Metabolite M6</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>C24 is the plasma concentration of uprifosbuvir metabolite M6 24 hours following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Uprifosbuvir Metabolite M6</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Tmax is the time required to reach the maximum post-dose plasma concentration of uprifosbuvir metabolite M6 following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t½ of Uprifosbuvir Metabolite M6</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>t1/2 is the amount of time required to clear 50% of uprifosbuvir metabolite M6 from plasma following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last of Grazoprevir (MK-5172)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>AUC0-last is a measure of total exposure to grazoprevir in plasma from the start of dosing to the time of the last quantifiable (&lt;LLOQ) sample following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ of Grazoprevir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>AUC0-∞ is a measure of total exposure to grazoprevir in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 of Grazoprevir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose</time_frame>
    <description>AUC0-24 is a measure of total exposure to grazoprevir in plasma from the start of dosing to 24 hours post-dose following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Grazoprevir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Cmax is the maximum amount of grazoprevir in plasma following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C24 of Grazoprevir</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>C24 is the plasma concentration of grazoprevir 24 hours following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Grazoprevir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Tmax is the time required to reach the maximum post-dose plasma concentration of grazoprevir following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of Grazoprevir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>CL/F is the apparent total body clearance of grazoprevir following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F of Grazoprevir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Vz/F is the apparent volume of distribution of grazoprevir following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t½ of Grazoprevir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>t1/2 is the amount of time required to clear 50% of grazoprevir from plasma following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last of Ruzasvir (MK-8408)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>AUC0-last is a measure of total exposure to ruzasvir in plasma from the start of dosing to the time of the last quantifiable (&lt;LLOQ) sample following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ of Ruzasvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>AUC0-∞ is a measure of total exposure to ruzasvir in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 of Ruzasvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose</time_frame>
    <description>AUC0-24 is a measure of total exposure to ruzasvir in plasma from dosing to 24 hours following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Ruzasvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Cmax is the maximum amount of ruzasvir in plasma following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C24 of Ruzasvir</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>C24 is the plasma concentration of ruzasvir 24 hours following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Ruzasvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Tmax is the time required to reach the maximum post-dose plasma concentration of ruzasvir following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of Ruzasvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>CL/F is the apparent total body clearance of ruzasvir following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F of Ruzasvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>Vz/F is the apparent volume of distribution of ruzasvir following oral administration of MK-3682B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t½ of Ruzasvir</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
    <description>t1/2 is the amount of time required to clear 50% of ruzasvir from plasma following oral administration of MK-3682B.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Moderate RI Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe RI Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with an eGFR of ≥15 mL/min/1.73m^2 to &lt;30 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants (creatinine clearance [CLcr] ≥80 mL/min) take 2 MK-362B FDC tablets on Day 1 after fasting for 10 hours. Healthy participants are matched to RI participants based on mean age, body mass index (BMI) and gender.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3682B</intervention_name>
    <description>FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.</description>
    <arm_group_label>Healthy Participants</arm_group_label>
    <arm_group_label>Moderate RI Participants</arm_group_label>
    <arm_group_label>Severe RI Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Participants:

          -  Healthy adult males or females 18-80 years of age at screening

          -  Continuous non-smokers or moderate smokers (≤ 20 cigarettes/day or the equivalent) and
             agrees to consume no more than 10 cigarettes per day during the study period

          -  BMI ≥ 18 and ≤ 40.0 kg/m^2

          -  Agrees not to become pregnant or father a child during participation in the study

          -  Females of childbearing potential must either be abstinent for 14 days prior to dosing
             and throughout the study or be using an acceptable birth control method

          -  Vasectomized or non-vasectomized males must agree to use a condom with spermicide or
             abstain from sexual intercourse from the first dose until 90 days after dosing

          -  Males must agree not to donate sperm from dosing until 90 days after dosing

        Moderate and Severe RI Participants:

          -  Baseline health is judged to be stable based on medical history, physical examination,
             laboratory profiles, vital signs, or electrocardiograms (ECGs), as deemed by the
             Investigator

          -  Has had no clinically significant change in renal status at least 1 month prior to
             dosing and is not currently or has not previously been on hemodialysis

          -  Moderate RI: has baseline eGFR ≥ 30 mL/min/1.73m^2 and &lt; 60 mL/min/1.73m^2, based on
             the Modification of Diet in Renal Disease (MDRD) equation at screening

          -  Severe RI: has baseline eGFR ≥ 15 mL/min/1.73m^2 and &lt; 30 mL/min/1.73m^2, based on the
             MDRD equation at screening

        Healthy Participants:

          -  Is within ± 10 years of the mean age of moderate and severe RI arms

          -  BMI is within 10% of the mean BMI of participants with moderate and severe RI arms

          -  Medically healthy with no clinically significant medical history, physical
             examination, laboratory profiles, vital signs, or ECGs, as deemed by the Investigator

          -  Baseline CLcr ≥ 80 mL/min based on Cockcroft-Gault equation at screening

        Exclusion Criteria:

          -  Is mentally or legally incapacitated or has significant emotional problems at the time
             of the screening

          -  History or presence of clinically significant medical or psychiatric condition or
             disease in the opinion of the Investigator

          -  History of any illness that, in the opinion of the Investigator, might confound the
             results of the study or poses an additional risk by participating in the study

          -  Is female and pregnant or lactating

          -  Positive results for the urine or saliva drug screen or urine or breath alcohol screen
             at screening or check-in unless the positive drug screen is due to prescription drug
             use that is approved by the Investigator and Sponsor

          -  Positive results at screening for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg), or hepatitis C virus (HCV)

          -  Seated heart rate is equal to or lower than 44 beats per minute (bpm) or higher than
             100 bpm at screening

          -  Has had a renal transplant or has had nephrectomy

          -  Donation of blood or had significant blood loss within 56 days prior to dosing of
             study drug, or donation of plasma within 7 days prior to dosing

          -  Has participated in another clinical trial within 28 days prior to dosing of study
             drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2016</study_first_posted>
  <results_first_submitted>May 17, 2018</results_first_submitted>
  <results_first_submitted_qc>December 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 14, 2018</results_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uprifosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In Part 1, adults with moderate renal impairment (RI; determined by estimated glomerular filtration rate [eGFR]), and healthy participants, were recruited at 2 sites in the US. Part 2 was intended to enroll severe RI participants but was not conducted based on results of a planned interim analysis of Part 1 data.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Moderate RI Participants</title>
          <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B fixed dose combination (FDC) tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
        </group>
        <group group_id="P2">
          <title>Healthy Participants</title>
          <description>Healthy participants (creatinine clearance [CLcr] ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Moderate RI Participants</title>
          <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
        </group>
        <group group_id="B2">
          <title>Healthy Participants</title>
          <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Healthy participants were matched to moderate RI participants based on age.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.6" spread="9.0"/>
                    <measurement group_id="B2" value="65.8" spread="2.6"/>
                    <measurement group_id="B3" value="67.7" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Healthy participants were matched to moderate RI participants based on gender.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Healthy participants were matched to moderate RI participants based on BMI.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.32" spread="4.023"/>
                    <measurement group_id="B2" value="30.11" spread="2.057"/>
                    <measurement group_id="B3" value="30.22" spread="3.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve (AUC) From Dosing to Time of Last Measurable Concentration (AUC0-last) of Uprifosbuvir (MK-3682)</title>
        <description>AUC0-last is a measure of total exposure to uprifosbuvir in plasma from the start of dosing to the time of the last quantifiable (&lt; lower limit of quantification [LLOQ]) sample following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve (AUC) From Dosing to Time of Last Measurable Concentration (AUC0-last) of Uprifosbuvir (MK-3682)</title>
          <description>AUC0-last is a measure of total exposure to uprifosbuvir in plasma from the start of dosing to the time of the last quantifiable (&lt; lower limit of quantification [LLOQ]) sample following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.55" lower_limit="6.22" upper_limit="11.8"/>
                    <measurement group_id="O2" value="4.23" lower_limit="3.08" upper_limit="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Geometric least-squares mean ratio (GMR) of AUC0-last in Moderate RI/Healthy Participants.</non_inferiority_desc>
            <param_type>GMR of AUC0-last in Moderate RI/Healthy</param_type>
            <param_value>2.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC From Dosing to Infinity (AUC0-∞) of Uprifosbuvir</title>
        <description>AUC0-∞ is a measure of total exposure to uprifosbuvir in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Dosing to Infinity (AUC0-∞) of Uprifosbuvir</title>
          <description>AUC0-∞ is a measure of total exposure to uprifosbuvir in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.56" lower_limit="6.24" upper_limit="11.7"/>
                    <measurement group_id="O2" value="4.28" lower_limit="3.12" upper_limit="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-∞ in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of AUC0-∞ in Moderate RI/Healthy</param_type>
            <param_value>2.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>2.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC From Dosing to 24 Hours Post-dose (AUC0-24) of Uprifosbuvir</title>
        <description>AUC0-24 is a measure of total exposure to uprifosbuvir in plasma from dosing to 24 hours following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Dosing to 24 Hours Post-dose (AUC0-24) of Uprifosbuvir</title>
          <description>AUC0-24 is a measure of total exposure to uprifosbuvir in plasma from dosing to 24 hours following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.54" lower_limit="6.22" upper_limit="11.7"/>
                    <measurement group_id="O2" value="4.24" lower_limit="3.08" upper_limit="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-24 in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of AUC0-24 in Moderate RI/Healthy</param_type>
            <param_value>2.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Uprifosbuvir</title>
        <description>Cmax is the maximum amount of uprifosbuvir in plasma following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Uprifosbuvir</title>
          <description>Cmax is the maximum amount of uprifosbuvir in plasma following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3030" lower_limit="2230" upper_limit="4110"/>
                    <measurement group_id="O2" value="1570" lower_limit="1160" upper_limit="2130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of Cmax in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of Cmax in Moderate RI/Healthy</param_type>
            <param_value>1.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration 24 Hours Post-dose (C24) of Uprifosbuvir</title>
        <description>C24 is the plasma concentration of uprifosbuvir 24 hours following oral administration of MK-3682B.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>All Healthy Control participants are included in the analysis. Since &gt;50% of participants in the Moderate RI group had C24 values &lt;LLOQ, no data are presented for this group as per Merck policy.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration 24 Hours Post-dose (C24) of Uprifosbuvir</title>
          <description>C24 is the plasma concentration of uprifosbuvir 24 hours following oral administration of MK-3682B.</description>
          <population>All Healthy Control participants are included in the analysis. Since &gt;50% of participants in the Moderate RI group had C24 values &lt;LLOQ, no data are presented for this group as per Merck policy.</population>
          <units>nM</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3.65" lower_limit="0.00" upper_limit="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) of Uprifosbuvir</title>
        <description>Tmax is the time required to reach the maximum post-dose plasma concentration of uprifosbuvir following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) of Uprifosbuvir</title>
          <description>Tmax is the time required to reach the maximum post-dose plasma concentration of uprifosbuvir following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.50" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Body Clearance (CL/F) of Uprifosbuvir</title>
        <description>CL/F is the apparent total body clearance of uprifosbuvir following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CL/F) of Uprifosbuvir</title>
          <description>CL/F is the apparent total body clearance of uprifosbuvir following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>Liters/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" spread="51.5"/>
                    <measurement group_id="O2" value="193" spread="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vz/F) of Uprifosbuvir</title>
        <description>Vz/F is the apparent volume of distribution of uprifosbuvir following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) of Uprifosbuvir</title>
          <description>Vz/F is the apparent volume of distribution of uprifosbuvir following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290" spread="51.7"/>
                    <measurement group_id="O2" value="724" spread="115.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half-life in Plasma (t½) of Uprifosbuvir</title>
        <description>t1/2 is the amount of time required to clear 50% of uprifosbuvir from plasma following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life in Plasma (t½) of Uprifosbuvir</title>
          <description>t1/2 is the amount of time required to clear 50% of uprifosbuvir from plasma following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="65.6"/>
                    <measurement group_id="O2" value="2.60" spread="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-last of Uprifosbuvir Metabolite M5</title>
        <description>AUC0-last is a measure of total exposure to uprifosbuvir metabolite M5 in plasma from the start of dosing to the time of the last quantifiable (&lt;LLOQ) sample following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-last of Uprifosbuvir Metabolite M5</title>
          <description>AUC0-last is a measure of total exposure to uprifosbuvir metabolite M5 in plasma from the start of dosing to the time of the last quantifiable (&lt;LLOQ) sample following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="11.1" upper_limit="19.6"/>
                    <measurement group_id="O2" value="7.62" lower_limit="5.74" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-last in Moderate RI/Healthy Participants.</non_inferiority_desc>
            <param_type>GMR of AUC0-last in Moderate RI/Healthy</param_type>
            <param_value>1.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>2.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ of Uprifosbuvir Metabolite M5</title>
        <description>AUC0-∞ is a measure of total exposure to uprifosbuvir metabolite M5 in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ of Uprifosbuvir Metabolite M5</title>
          <description>AUC0-∞ is a measure of total exposure to uprifosbuvir metabolite M5 in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="12.5" upper_limit="20.8"/>
                    <measurement group_id="O2" value="7.99" lower_limit="6.19" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-∞ in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of AUC0-∞ in Moderate RI/Healthy</param_type>
            <param_value>2.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.50</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-24 of Uprifosbuvir Metabolite M5</title>
        <description>AUC0-24 is a measure of total exposure to uprifosbuvir metabolite M5 in plasma from dosing to 24 hours following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24 of Uprifosbuvir Metabolite M5</title>
          <description>AUC0-24 is a measure of total exposure to uprifosbuvir metabolite M5 in plasma from dosing to 24 hours following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" lower_limit="3.25" upper_limit="6.47"/>
                    <measurement group_id="O2" value="2.67" lower_limit="1.89" upper_limit="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-24 in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of AUC0-24 in Moderate RI/Healthy</param_type>
            <param_value>1.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Uprifosbuvir Metabolite M5</title>
        <description>Cmax is the maximum amount of uprifosbuvir metabolite M5 in plasma following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Uprifosbuvir Metabolite M5</title>
          <description>Cmax is the maximum amount of uprifosbuvir metabolite M5 in plasma following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321" lower_limit="220" upper_limit="467"/>
                    <measurement group_id="O2" value="173" lower_limit="119" upper_limit="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of Cmax in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of Cmax in Moderate RI/Healthy</param_type>
            <param_value>1.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>2.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C24 of Uprifosbuvir Metabolite M5</title>
        <description>C24 is the plasma concentration of uprifosbuvir metabolite M5 24 hours following oral administration of MK-3682B.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>C24 of Uprifosbuvir Metabolite M5</title>
          <description>C24 is the plasma concentration of uprifosbuvir metabolite M5 24 hours following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262" lower_limit="189" upper_limit="365"/>
                    <measurement group_id="O2" value="129" lower_limit="93.0" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of C24 in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of C24 in Moderate RI/Healthy</param_type>
            <param_value>2.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>2.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Uprifosbuvir Metabolite M5</title>
        <description>Tmax is the time required to reach the maximum post-dose plasma concentration of uprifosbuvir metabolite M5 following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Uprifosbuvir Metabolite M5</title>
          <description>Tmax is the time required to reach the maximum post-dose plasma concentration of uprifosbuvir metabolite M5 following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00" lower_limit="10.00" upper_limit="24.00"/>
                    <measurement group_id="O2" value="13.00" lower_limit="12.00" upper_limit="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lag Time (Tlag) of Uprifosbuvir Metabolite M5</title>
        <description>Tlag is the time from dosing to first appearance in plasma of uprifosbuvir metabolite M5 following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Lag Time (Tlag) of Uprifosbuvir Metabolite M5</title>
          <description>Tlag is the time from dosing to first appearance in plasma of uprifosbuvir metabolite M5 following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="2.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="2.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t½ of Uprifosbuvir Metabolite M5</title>
        <description>t1/2 is the amount of time required to clear 50% of uprifosbuvir metabolite M5 from plasma following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>t½ of Uprifosbuvir Metabolite M5</title>
          <description>t1/2 is the amount of time required to clear 50% of uprifosbuvir metabolite M5 from plasma following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.27" spread="45.0"/>
                    <measurement group_id="O2" value="25.33" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-last of Uprifosbuvir Metabolite M6</title>
        <description>AUC0-last is a measure of total exposure to uprifosbuvir metabolite M6 in plasma from the start of dosing to the time of the last quantifiable (&lt;LLOQ) sample following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-last of Uprifosbuvir Metabolite M6</title>
          <description>AUC0-last is a measure of total exposure to uprifosbuvir metabolite M6 in plasma from the start of dosing to the time of the last quantifiable (&lt;LLOQ) sample following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" lower_limit="50.1" upper_limit="81.5"/>
                    <measurement group_id="O2" value="33.5" lower_limit="26.3" upper_limit="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-last in Moderate RI/Healthy Participants.</non_inferiority_desc>
            <param_type>GMR of AUC0-last in Moderate RI/Healthy</param_type>
            <param_value>1.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.44</ci_lower_limit>
            <ci_upper_limit>2.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ of Uprifosbuvir Metabolite M6</title>
        <description>AUC0-∞ is a measure of total exposure to uprifosbuvir metabolite M6 in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ of Uprifosbuvir Metabolite M6</title>
          <description>AUC0-∞ is a measure of total exposure to uprifosbuvir metabolite M6 in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="55.8" upper_limit="91.3"/>
                    <measurement group_id="O2" value="36.2" lower_limit="28.3" upper_limit="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-∞ in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of AUC0-∞ in Moderate RI/Healthy</param_type>
            <param_value>1.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.48</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-24 of Uprifosbuvir Metabolite M6</title>
        <description>AUC0-24 is a measure of total exposure to uprifosbuvir metabolite M6 in plasma from dosing to 24 hours following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24 of Uprifosbuvir Metabolite M6</title>
          <description>AUC0-24 is a measure of total exposure to uprifosbuvir metabolite M6 in plasma from dosing to 24 hours following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" lower_limit="22.2" upper_limit="33.4"/>
                    <measurement group_id="O2" value="13.9" lower_limit="11.3" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-24 in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of AUC0-24 in Moderate RI/Healthy</param_type>
            <param_value>1.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.54</ci_lower_limit>
            <ci_upper_limit>2.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Uprifosbuvir Metabolite M6</title>
        <description>Cmax is the maximum amount of uprifosbuvir metabolite M6 in plasma following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Uprifosbuvir Metabolite M6</title>
          <description>Cmax is the maximum amount of uprifosbuvir metabolite M6 in plasma following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1540" lower_limit="1210" upper_limit="1950"/>
                    <measurement group_id="O2" value="906" lower_limit="715" upper_limit="1150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of Cmax in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of Cmax in Moderate RI/Healthy</param_type>
            <param_value>1.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>2.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C24 of Uprifosbuvir Metabolite M6</title>
        <description>C24 is the plasma concentration of uprifosbuvir metabolite M6 24 hours following oral administration of MK-3682B.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>C24 of Uprifosbuvir Metabolite M6</title>
          <description>C24 is the plasma concentration of uprifosbuvir metabolite M6 24 hours following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="905" lower_limit="712" upper_limit="1150"/>
                    <measurement group_id="O2" value="466" lower_limit="367" upper_limit="592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of C24 in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of C24 in Moderate RI/Healthy</param_type>
            <param_value>1.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.47</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Uprifosbuvir Metabolite M6</title>
        <description>Tmax is the time required to reach the maximum post-dose plasma concentration of uprifosbuvir metabolite M6 following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Uprifosbuvir Metabolite M6</title>
          <description>Tmax is the time required to reach the maximum post-dose plasma concentration of uprifosbuvir metabolite M6 following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" lower_limit="3.00" upper_limit="10.00"/>
                    <measurement group_id="O2" value="3.50" lower_limit="3.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t½ of Uprifosbuvir Metabolite M6</title>
        <description>t1/2 is the amount of time required to clear 50% of uprifosbuvir metabolite M6 from plasma following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>t½ of Uprifosbuvir Metabolite M6</title>
          <description>t1/2 is the amount of time required to clear 50% of uprifosbuvir metabolite M6 from plasma following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.58" spread="39.7"/>
                    <measurement group_id="O2" value="30.55" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-last of Grazoprevir (MK-5172)</title>
        <description>AUC0-last is a measure of total exposure to grazoprevir in plasma from the start of dosing to the time of the last quantifiable (&lt;LLOQ) sample following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-last of Grazoprevir (MK-5172)</title>
          <description>AUC0-last is a measure of total exposure to grazoprevir in plasma from the start of dosing to the time of the last quantifiable (&lt;LLOQ) sample following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.974" lower_limit="0.523" upper_limit="1.81"/>
                    <measurement group_id="O2" value="0.730" lower_limit="0.392" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-last in Moderate RI/Healthy Participants.</non_inferiority_desc>
            <param_type>GMR of AUC0-last in Moderate RI/Healthy</param_type>
            <param_value>1.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ of Grazoprevir</title>
        <description>AUC0-∞ is a measure of total exposure to grazoprevir in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants except 1 are included in the analysis. One participant in the Moderate RI group did not have a well characterized terminal phase and their value was set to &quot;missing&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ of Grazoprevir</title>
          <description>AUC0-∞ is a measure of total exposure to grazoprevir in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
          <population>All participants except 1 are included in the analysis. One participant in the Moderate RI group did not have a well characterized terminal phase and their value was set to &quot;missing&quot;.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="0.708" upper_limit="2.45"/>
                    <measurement group_id="O2" value="0.826" lower_limit="0.463" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-∞ in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of AUC0-∞ in Moderate RI/Healthy</param_type>
            <param_value>1.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>3.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-24 of Grazoprevir</title>
        <description>AUC0-24 is a measure of total exposure to grazoprevir in plasma from the start of dosing to 24 hours post-dose following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24 of Grazoprevir</title>
          <description>AUC0-24 is a measure of total exposure to grazoprevir in plasma from the start of dosing to 24 hours post-dose following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.436" lower_limit="0.218" upper_limit="0.875"/>
                    <measurement group_id="O2" value="0.380" lower_limit="0.190" upper_limit="0.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-24 in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of AUC0-24 in Moderate RI/Healthy</param_type>
            <param_value>1.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Grazoprevir</title>
        <description>Cmax is the maximum amount of grazoprevir in plasma following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Grazoprevir</title>
          <description>Cmax is the maximum amount of grazoprevir in plasma following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" lower_limit="31.0" upper_limit="147"/>
                    <measurement group_id="O2" value="54.7" lower_limit="25.1" upper_limit="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of Cmax in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of Cmax in Moderate RI/Healthy</param_type>
            <param_value>1.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C24 of Grazoprevir</title>
        <description>C24 is the plasma concentration of grazoprevir 24 hours following oral administration of MK-3682B.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>C24 of Grazoprevir</title>
          <description>C24 is the plasma concentration of grazoprevir 24 hours following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.41" lower_limit="4.64" upper_limit="19.1"/>
                    <measurement group_id="O2" value="7.36" lower_limit="3.63" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of C24 in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of C24 in Moderate RI/Healthy</param_type>
            <param_value>1.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>2.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Grazoprevir</title>
        <description>Tmax is the time required to reach the maximum post-dose plasma concentration of grazoprevir following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Grazoprevir</title>
          <description>Tmax is the time required to reach the maximum post-dose plasma concentration of grazoprevir following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.25" lower_limit="1.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F of Grazoprevir</title>
        <description>CL/F is the apparent total body clearance of grazoprevir following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants except 1 are included in the analysis. One participant in the Moderate RI group did not have a well characterized terminal phase and their value was set to &quot;missing&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F of Grazoprevir</title>
          <description>CL/F is the apparent total body clearance of grazoprevir following oral administration of MK-3682B.</description>
          <population>All participants except 1 are included in the analysis. One participant in the Moderate RI group did not have a well characterized terminal phase and their value was set to &quot;missing&quot;.</population>
          <units>Liters/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" spread="122.0"/>
                    <measurement group_id="O2" value="158" spread="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vz/F of Grazoprevir</title>
        <description>Vz/F is the apparent volume of distribution of grazoprevir following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants except 1 are included in the analysis. One participant in the Moderate RI group did not have a well characterized terminal phase and their value was set to &quot;missing&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F of Grazoprevir</title>
          <description>Vz/F is the apparent volume of distribution of grazoprevir following oral administration of MK-3682B.</description>
          <population>All participants except 1 are included in the analysis. One participant in the Moderate RI group did not have a well characterized terminal phase and their value was set to &quot;missing&quot;.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6030" spread="183.5"/>
                    <measurement group_id="O2" value="9750" spread="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t½ of Grazoprevir</title>
        <description>t1/2 is the amount of time required to clear 50% of grazoprevir from plasma following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants except 1 are included in the analysis. One participant in the Moderate RI group did not have a well characterized terminal phase and their value was set to &quot;missing&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>t½ of Grazoprevir</title>
          <description>t1/2 is the amount of time required to clear 50% of grazoprevir from plasma following oral administration of MK-3682B.</description>
          <population>All participants except 1 are included in the analysis. One participant in the Moderate RI group did not have a well characterized terminal phase and their value was set to &quot;missing&quot;.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.21" spread="40.3"/>
                    <measurement group_id="O2" value="42.85" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-last of Ruzasvir (MK-8408)</title>
        <description>AUC0-last is a measure of total exposure to ruzasvir in plasma from the start of dosing to the time of the last quantifiable (&lt;LLOQ) sample following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-last of Ruzasvir (MK-8408)</title>
          <description>AUC0-last is a measure of total exposure to ruzasvir in plasma from the start of dosing to the time of the last quantifiable (&lt;LLOQ) sample following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" lower_limit="1.60" upper_limit="2.67"/>
                    <measurement group_id="O2" value="1.32" lower_limit="1.03" upper_limit="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-last in Moderate RI/Healthy Participants.</non_inferiority_desc>
            <param_type>GMR of AUC0-last in Moderate RI/Healthy</param_type>
            <param_value>1.56</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ of Ruzasvir</title>
        <description>AUC0-∞ is a measure of total exposure to ruzasvir in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ of Ruzasvir</title>
          <description>AUC0-∞ is a measure of total exposure to ruzasvir in plasma from the start of dosing to infinity following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1.71" upper_limit="2.81"/>
                    <measurement group_id="O2" value="1.40" lower_limit="1.09" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-∞ in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of AUC0-∞ in Moderate RI/Healthy</param_type>
            <param_value>1.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-24 of Ruzasvir</title>
        <description>AUC0-24 is a measure of total exposure to ruzasvir in plasma from dosing to 24 hours following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24 of Ruzasvir</title>
          <description>AUC0-24 is a measure of total exposure to ruzasvir in plasma from dosing to 24 hours following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>uM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="0.872" upper_limit="1.42"/>
                    <measurement group_id="O2" value="0.744" lower_limit="0.583" upper_limit="0.948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of AUC0-24 in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of AUC0-24 in Moderate RI/Healthy</param_type>
            <param_value>1.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Ruzasvir</title>
        <description>Cmax is the maximum amount of ruzasvir in plasma following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Ruzasvir</title>
          <description>Cmax is the maximum amount of ruzasvir in plasma following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="88.9" upper_limit="154"/>
                    <measurement group_id="O2" value="80.9" lower_limit="61.6" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of Cmax in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of Cmax in Moderate RI/Healthy</param_type>
            <param_value>1.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C24 of Ruzasvir</title>
        <description>C24 is the plasma concentration of ruzasvir 24 hours following oral administration of MK-3682B.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>C24 of Ruzasvir</title>
          <description>C24 is the plasma concentration of ruzasvir 24 hours following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="18.5" upper_limit="30.8"/>
                    <measurement group_id="O2" value="15.5" lower_limit="12.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMR of C24 in Moderate RI/Healthy Participants</non_inferiority_desc>
            <param_type>GMR of C24 in Moderate RI/Healthy</param_type>
            <param_value>1.54</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Ruzasvir</title>
        <description>Tmax is the time required to reach the maximum post-dose plasma concentration of ruzasvir following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Ruzasvir</title>
          <description>Tmax is the time required to reach the maximum post-dose plasma concentration of ruzasvir following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F of Ruzasvir</title>
        <description>CL/F is the apparent total body clearance of ruzasvir following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F of Ruzasvir</title>
          <description>CL/F is the apparent total body clearance of ruzasvir following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>Liters/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" spread="34.5"/>
                    <measurement group_id="O2" value="48.8" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vz/F of Ruzasvir</title>
        <description>Vz/F is the apparent volume of distribution of ruzasvir following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F of Ruzasvir</title>
          <description>Vz/F is the apparent volume of distribution of ruzasvir following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1410" spread="40.0"/>
                    <measurement group_id="O2" value="2060" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t½ of Ruzasvir</title>
        <description>t1/2 is the amount of time required to clear 50% of ruzasvir from plasma following oral administration of MK-3682B.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose</time_frame>
        <population>All participants are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate RI Participants</title>
            <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>t½ of Ruzasvir</title>
          <description>t1/2 is the amount of time required to clear 50% of ruzasvir from plasma following oral administration of MK-3682B.</description>
          <population>All participants are included in the analysis.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.50" spread="11.4"/>
                    <measurement group_id="O2" value="29.31" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days</time_frame>
      <desc>An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. All 16 participants were included in the safety and tolerability assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Moderate RI Participants</title>
          <description>Participants with an eGFR of ≥30 mL/min/1.73m^2 to &lt;60 mL/min/1.73m^2 took 2 MK-3682B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
        </group>
        <group group_id="E2">
          <title>Healthy Participants</title>
          <description>Healthy participants (CLcr ≥80 mL/min) took 2 MK-362B FDC tablets (225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir per tablet) on Day 1 after fasting for 10 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v. 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

